Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a ...

The new branding also precedes GSK’s proposed demerger this year, which will mean it focuses entirely on biopharma innovation, while its consumer healthcare business, Haleon ... elements of the ...

Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer ...

Pfizer is set to raise £2.5bn by selling a 7.7% stake in Haleon, the UK consumer healthcare company, in a block trade on ...